Prostate cancer patients weigh in: which chemo is easier to tolerate?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Affiliated to a social security regimen ; * Male patients older than 18 years ; * Histologically confirmed adenocarcinoma of the prostate ; * Continued androgen deprivation therapy either by LHRH agonists/antagonists or orchidectomy ; * Serum testosterone \<0.50 ng/ml (1.7 nmol/L) ; * Progressive disease (PSA progression or radiological progression or clinical progression) ; * ECOG 0-2 ; * Information delivered to patient and informed consent form signed by the patient or his legal representative ; * Adequate organ or bone marrow function as evidenced by: * Hemoglobin \>/= 10 g/dL * Absolute neutrophil count \>/=1.5 x 109/L, * Platelet count \>/=100 x 109/L, * AST/SGOT and/or ALT/SGPT \</=1.5 x ULN; * Total bilirubin \</=1.5 x ULN, * Serum creatinine \</=1.5 x ULN. If creatinine 1.0 - 1.5 xULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60 mL/min should be excluded Exclusion Criteria: * Patients having received an investigational drug and/or prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior enrolment in the study, excepted radiotherapy directed to a single bone lesions which is nonacceptable if within 2 weeks ; * Prior treatment with Taxotere or Jevtana ; * Pre-existing symptomatic peripheral neuropathy grade \> 2 (CTCAE V4) ; * Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction within last 6 months is also not allowed ; * History of severe hypersensitivity reaction (grade ≥3) to polysorbate 80 containing drugs ; * Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus), active infection including HIV infection, active Hepatitis B or C infection that would preclude participation in the trial ; * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) ;